REGENXBIO to Participate in Upcoming Investor Conferences

2024-03-11

基因疗法

ROCKVILLE, Md., March 11, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences:

Leerink Partners 2024 Global Biopharma Conference

Date: Tuesday, March 12, 2024

Location: Miami, FL

1x1 investor meetings only

Barclays 26th Annual Global Healthcare Conference

Fireside Chat: Wednesday, March 13, 2024 at 4:05 p.m. ET

Gene Therapy Regulatory Path in Rare Diseases Panel: Wednesday, March 13, 2024 at 4:35 p.m. ET

Location: Miami, FL

UBS Virtual CNS Day

Fireside Chat: Monday, March 18, 2024 at 3:30 p.m. ET

Location: Virtual

A live webcast of the fireside chat at the Barclays conference can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.

Contacts:

Dana Cormack

Corporate Communications

[email protected]

Investors:

Chris Brinzey, ICR Westwicke

339-970-2843

[email protected]

SOURCE REGENXBIO Inc.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构